Nurix Therapeutics
E3 ligase-based platform for targeted protein degradation in cancer
- Sector
- Biotech
- Founded
- 2009
- Latest Form D
- $120M, Mar 2020
- Total capital
- $142M
- Federal grants
- None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
- Private capital raised
- $142M
- 5 Form D · last Mar 2020
- 79 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 18
- 22 pending · first 2022
- Rank in peer group#94 of 1449
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 5th filing$120M
- Private capital raisedForm D · SEC · 4th filing$17M
- Private capital raisedForm D · SEC · 3rd filing$2.1M
- Private capital raisedForm D · SEC · 2nd filing$2K
- Private capital raisedForm D · SEC · 1st filing$3.1M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 1449 peers
Line = medianBiotech · Molecule
- Granted patents#94 · top 6%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
Researcher links verified by same-company patents and grants- Arthur SandsResearcherExecutive Officer, DirectorLinked by 1 patent
- Christine RingExecutive OfficerNamed in SEC Form D filings
- David LaceyDirectorNamed in SEC Form D filings
- Hans van HouteExecutive OfficerNamed in SEC Form D filings
- Jeff TongDirectorNamed in SEC Form D filings
- Julia GregoryDirectorNamed in SEC Form D filings
Show all 9 people
- Leon ChenDirectorNamed in SEC Form D filings
- Lori KunkelDirectorNamed in SEC Form D filings
- Robert TjianDirectorNamed in SEC Form D filings
What it has protected
USPTO · 18 granted of 40- PendingBifunctional Selective Degraders Of SMARCA2 And Therapeutic Uses ThereofUSPTOApplication 19416581
- PendingBifunctional Compounds For Degrading Btk Via Ubiquitin Proteosome PathwayUSPTOApplication 19552781
- GrantedUrea, Amide, And Substituted Heteroaryl Compounds For Cbl-b InhibitionUSPTOUS 12,653,809
Show all 40 patent records
- Bifunctional Selective Degraders Of SMARCA2 And Therapeutic Uses ThereofJul 23, 2026 · Application 19416581Pending
- Bifunctional Compounds For Degrading Btk Via Ubiquitin Proteosome PathwayJul 9, 2026 · Application 19552781Pending
- Urea, Amide, And Substituted Heteroaryl Compounds For Cbl-b InhibitionJun 16, 2026 · US 12,653,809Granted
- Bifunctional Compounds For Degrading Btk Via Ubiquitin Proteosome PathwayApr 14, 2026 · US 12,600,732Granted
- Cbl Inhibitors And Compositions For Expansion Of Immune CellsApr 7, 2026 · US 12,594,263Granted
- Bifunctional Compounds For Degrading Btk Via Ubiquitin Proteosome PathwayMar 24, 2026 · US 12,582,722Granted
- Bifunctional Compounds For Degrading Btk Via Ubiquitin Proteosome PathwayMar 24, 2026 · US 12,583,862Granted
- Bifunctional Compounds For Degrading Btk Via Ubiquitin Proteosome PathwayFeb 5, 2026 · Application 19353387Pending
- 3-SUBSTITUTED Piperidine Compounds For Cbl-b Inhibition, And Use ThereofDec 2, 2025 · US 12,485,144Granted
- Piperidinylpyrazine-carboxamide Compounds For Treating And Preventing Cancer And For Degrading BtkAug 5, 2025 · US 12,377,106Granted
- Combination Therapies With Cbl-b Inhibitor CompoundsMay 22, 2025 · Application 18662924Pending
- Substituted Benzyl-triazole Compounds For Cbl-b Inhibition, And Further Uses ThereofMay 1, 2025 · Application 18927712Pending
- Salts And Free Bases Of Bifunctional Compound And Polymorph Forms ThereofMay 1, 2025 · Application 18923580Pending
- Substituted Benzyl-triazole Compounds For Cbl-b Inhibition, And Further Uses ThereofFeb 25, 2025 · US 12,234,230Granted
- Bifunctional Selective Degraders Of SMARCA2 And Therapeutic Uses ThereofFeb 13, 2025 · Application 18737832Pending
- Bifunctional Compounds For Degrading Btk With Enhanced Imid ActivityJan 16, 2025 · Application 18290920Pending
- Toll-like Receptor Therapy Combinations With Cbl-b Inhibitor CompoundsJan 9, 2025 · Application 18708175Pending
- Bifunctional Compounds For Degrading Itk Via Ubiquitin Proteosome PathwayJan 2, 2025 · Application 18702666Pending
- Cyano Cyclobutyl Compounds For Cbl-b Inhibition And Uses ThereofDec 12, 2024 · Application 18747129Pending
- Cbl Inhibitors And Compositions For Use In Adoptive Cell TherapyOct 22, 2024 · US 12,121,540Granted
- Bifunctional Compounds For Degrading Btk With Diminished Imid ActivityOct 10, 2024 · Application 18579114Pending
- Compounds For Inhibiting Or Degrading Itk, Compositions, Comprising The Same Methods Of Their Making And Methods Of Their UseAug 22, 2024 · Application 18289513Pending
- Cyano Cyclobutyl Compounds For Cbl-b Inhibition And Uses ThereofJul 30, 2024 · US 12,049,471Granted
- Combination Therapies With Cbl-b Inhibitor CompoundsJun 25, 2024 · US 12,016,860Granted
- 3-SUBSTITUTED Piperidine Compounds For Cbl-b Inhibition, And Use ThereofApr 9, 2024 · US 11,951,133Granted
- Bifunctional Compounds For Degrading Btk Via Ubiquitin Proteosome PathwayJan 9, 2024 · US 11,866,442Granted
- Combination Therapies With Cbl-b Inhibitor Compounds And Antiemetic AgentsDec 28, 2023 · Application 18213177Pending
- Bifunctional Compounds For Degrading Btk Via Ubiquitin Proteosome PathwayNov 21, 2023 · US 11,820,781Granted
- Biomarkers For Cbl, And Compositions And Methods For Their UseNov 9, 2023 · Application 18302603Pending
- Compounds For Inhibiting Or Degrading Target Proteins, Compositions, Comprising The Same, Methods Of Their Making, And Methods Of Their UseMay 25, 2023 · Application 17889062Pending
- Bifunctional Compounds For Grading Btk Via Ubiquitin Proteosome PathwayJan 26, 2023 · Application 17775265Pending
- Cyano Cyclobutyl Compounds For Cbl-b Inhibition And Uses ThereofDec 20, 2022 · US 11,530,229Granted
- Bifunctional Compounds For Degrading Btk Via Ubiquitin Proteosome PathwayOct 25, 2022 · US 11,479,556Granted
- Inhibitors Of Cbl-b And Methods Of Use ThereofOct 13, 2022 · Application 16964979Pending
- 3-SUBSTITUTED Piperidine Compounds For Cbl-b Inhibition, And Use ThereofOct 11, 2022 · US 11,464,802Granted
- Substituted Benzyl-triazole Compounds For Cbl-b Inhibition, And Further Uses ThereofAug 2, 2022 · US 11,401,267Granted
- Salts And Free Bases Of Bifunctional Compound And Polymorph Forms ThereofApplication 63545346Pending
- Purification Methods For Achiral And Chiral CompoundsApplication 63765470Pending
- Salts And Free Bases Of Bifunctional Compound And Polymorph Forms ThereofApplication 63670621Pending
- Bifunctional Selective Degraders Of SMARCA2 And Therapeutic Uses ThereofApplication 63730921Pending
Related companies, and why
- AERIE PHARMACEUTICALS INCSimilar federal contract value in Biotech · null in contracts
- Gate BioscienceSimilar federal contract value in Biotech · null in contracts
- InsitroSimilar federal contract value in Biotech · null in contracts
- FIVE ELEVEN PHARMA, INC.Similar federal contract value in Biotech · null in contracts
- Z BIOTECH, LLCSimilar federal contract value in Biotech · null in contracts
- Antios Therapeutics Inc.Similar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .